Table 3

Clinical Outcomes at 9 Months

Tryton Stent
(N = 355)
Provisional
(N = 349)
p Value
TVF60/345 (17.4)43/337 (12.8)0.11
Death4/347 (1.2)4/337 (1.2)1.00
 Cardiac0/343 (0.0)0/333 (0.0)
 Noncardiac4/347 (1.2)4/337 (1.2)1.00
Target vessel MI52/345 (15.1)36/337 (10.7)0.11
 Q-wave2/343 (0.6)1/333 (0.3)1.00
 Non–Q-wave50/345 (14.5)34/337 (10.1)0.08
Nontarget vessel MI2/343 (0.6)2/334 (0.6)1.00
 Q-wave0/343 (0.0)0/333 (0.0)
 Non–Q-wave2/343 (0.6)2/334 (0.6)1.00
Modified ARC MI54/345 (15.7)38/338 (11.2)0.09
 Periprocedural PCI47/345 (13.6)34/336 (10.1)0.19
 Peri-CABG1/343 (0.3)0/333 (0.0)1.00
 Spontaneous7/343 (2.0)5/335 (1.5)0.77
 Sudden death0/343 (0.0)0/333 (0.0)
 Reinfarction0/343 (0.0)0/333 (0.0)
 Q-wave MI2/343 (0.6)1/333 (0.3)1.00
 Non–Q-wave MI52/345 (15.1)36/338 (10.7)0.09
TVR19/344 (5.5)13/335 (3.9)0.37
 Clinically driven TVR16/343 (4.7)12/334 (3.6)0.56
 Nonclinically driven TVR4/344 (1.2)2/334 (0.6)0.69
 MB14/343 (4.1)10/334 (3.0)0.54
 SB9/343 (2.6)5/334 (1.5)0.42
Non-TVR13/343 (3.8)12/333 (3.6)1.00
Target lesion revascularization17/344 (4.9)11/335 (3.3)0.34
 Clinically driven target lesion revascularization14/343 (4.1)10/334 (3.0)0.54
 Nonclinically driven target lesion revascularization3/344 (0.9)2/334 (0.6)1.00
 MB12/343 (3.5)8/334 (2.4)0.50
 SB9/343 (2.6)5/334 (1.5)0.42
ARC-defined stent thrombosis (definite, probable)2/343 (0.6)1/334 (0.3)1.00
 MB2/343 (0.6)1/334 (0.3)1.00
 SB2/343 (0.6)0/333 (0.0)0.50
MACE (death, MI, emergent CABG, clinically driven TLR)65/349 (18.6)45/340 (13.2)0.06

Values are n/N (%).

ARC = Academic Research Consortium; MACE = major adverse cardiac event(s); MB = main branch SB = side branch; TLR = target lesion revascularization; TVF = target vessel failure; TVR = target vessel revascularization; other abbreviations as in Table 1.

  • Defined as cardiac death, target vessel MI, or clinically driven TVR.

  • Cumulative of target vessel, nontarget vessel, and undetermined vessel.